Affimed EBITDA 2014-2024 | AFMDQ
Affimed ebitda from 2014 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Affimed Annual EBITDA
(Millions of US $) |
| 2023 |
$-114 |
| 2022 |
$-90 |
| 2021 |
$-74 |
| 2020 |
$-38 |
| 2019 |
$-35 |
| 2018 |
$-23 |
| 2017 |
$-30 |
| 2016 |
$-35 |
| 2015 |
$-23 |
| 2014 |
$-10 |
| 2013 |
$7 |
| 2012 |
$2 |
Affimed Quarterly EBITDA
(Millions of US $) |
| 2024-09-30 |
$-15 |
| 2024-06-30 |
$-16 |
| 2024-03-31 |
$-19 |
| 2023-12-31 |
$-22 |
| 2023-09-30 |
$-26 |
| 2023-06-30 |
$-32 |
| 2023-03-31 |
$-33 |
| 2022-12-31 |
$-29 |
| 2022-09-30 |
$-19 |
| 2022-06-30 |
$-23 |
| 2022-03-31 |
$-19 |
| 2021-12-31 |
$-28 |
| 2021-09-30 |
$-22 |
| 2021-06-30 |
$-20 |
| 2021-03-31 |
$-5 |
| 2020-12-31 |
$-13 |
| 2020-09-30 |
$-3 |
| 2020-06-30 |
$-12 |
| 2020-03-31 |
$-11 |
| 2019-12-31 |
$-12 |
| 2019-09-30 |
$-13 |
| 2019-06-30 |
$-11 |
| 2019-03-31 |
$1 |
| 2018-12-31 |
$12 |
| 2018-09-30 |
$-14 |
| 2018-06-30 |
$-11 |
| 2018-03-31 |
$-10 |
| 2017-12-31 |
$-7 |
| 2017-09-30 |
$-8 |
| 2017-06-30 |
$-7 |
| 2017-03-31 |
$-8 |
| 2016-12-31 |
$-7 |
| 2016-09-30 |
$-11 |
| 2016-06-30 |
$-9 |
| 2016-03-31 |
$-8 |
| 2015-12-31 |
$-8 |
| 2015-09-30 |
$-8 |
| 2015-06-30 |
$-6 |
| 2015-03-31 |
$-2 |
| 2014-12-31 |
$0 |
| 2014-09-30 |
$-1 |
| 2014-06-30 |
$1 |
| 2014-03-31 |
$1 |
| 2013-09-30 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.009B |
|
Affimed N.V is a clinical stage biopharmaceutical company. It is engaged in developing single and combination therapies to treat cancers. The company's product pipeline consists of AFM13, AFM24, AFM26, AFM11 and AMV564 which are in clinical stage. Affimed N.V, formerly known as Affimed Therapeutics B.V., is based in Heidelberg, Germany.
|
